BV-R2 combination shows survival benefit across high-risk subgroups.
Martina Nasralla, PharmD Candidate
Advertisement
Articles by Martina Nasralla, PharmD Candidate
Discover the latest advancements in multiple myeloma treatment, including new therapies and FDA approvals that enhance patient outcomes and survival rates.
Intravenous immunoglobulin (IVIG) is a vital treatment for immunodeficiency and autoimmune disorders, with diverse mechanisms, brand-specific differences, and patient-centered considerations shaping safe and effective use.
Though new treatments offer hope, careful monitoring and understanding of risks remain essential for their success.
Advertisement
Latest Updated Articles
Multiple Myeloma: A Modern Look at an Ancient Disease and 2025’s Therapeutic BreakthroughsPublished: August 6th 2025 | Updated:
IVIG Therapy: Mechanisms, Formulations, and Key Considerations for Safe and Effective UsePublished: August 3rd 2025 | Updated:
Advertisement
Advertisement
Trending on Pharmacy Times
1
Eli Lilly, Novo Nordisk Strike MFN Deals With Trump Administration to Lower GLP-1 Prices
2
Environmental Factors Could Influence Type 1 Diabetes Risk in Children Through Epigenetic Changes
3
Less Common Pneumococcal Serotypes Cause More Severe Community-Acquired Pneumonia
4
FDA Approves Daratumumab and Hyaluronidase-fihj for High-Risk Smoldering Multiple Myeloma
5
